top of page

PRECEDE at the John R. Lewis Legacy Institute

Watch the video presentation at The Legacy Continues Gala on February 18, 2023.


What is PRECEDE?


The Pancreatic Cancer Early Detection (PRECEDE) Consortium is an international, multi-institutional collaborative group of experts to increase survival for pancreatic cancer patients by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer, through a novel model of collaboration and data sharing. PRECEDE’s mission is to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10% to 50% within the next 10 years. With 48 leading academic medical centers across the globe, PRECEDE has assembled the largest high-risk patient cohort, with longitudinal clinical data and biospecimen acquisition and tracking.



Comments


bottom of page